The trial, conducted at the Medical University of Vienna under the leadership of Univ. Prof. Dr. med. Markus Zeitlinger, investigated the safety, tolerability, and pharmacokinetics of subcutaneous recombinant human superoxide dismutase (rhSOD). As part of the study, investigators used Scarletred®Vision to capture and quantify injection site reactions (ISR). Our patented Standardized Erythema Value (SEV*), combined with AI-powered analytical tools from Arora® v1, enabled precise measurement of local tolerability parameters, providing an objective layer of assessment rarely achieved in Phase I ISR evaluation.

In addition, Scarletred successfully developed and validated a new electronic patient-reported outcome (ePRO) tool: the Subjects’ Perception of Injection (SUPI). SUPI captures subjective ISR parameters such as pain, redness, itching, swelling, induration, and bruising, complementing the image-based objective measurements and enabling a holistic ISR assessment framework.

This publication also highlights the early foundations of our current AI system. Over the past five years, Scarletred®Vision and our AI platform Arora® have continuously evolved, from the first-generation tools used in this study to the advanced, fully validated technology we offer today. Developed amidst the unprecedented challenges of the pandemic, this pivotal chapter in Arora’s® journey not only strengthened our capabilities but also accelerated the digital transformation of ISR monitoring, setting a new standard for objective, AI-powered clinical assessment.

The findings underscore the potential of rhSOD as a therapeutic candidate for conditions involving oxidative stress and open new pathways for future clinical applications. Scarletred remains committed to advancing this research and exploring the next steps for SOD-based therapies.

‍

Read the full publication

‍